Chongqing Zhifei Biological Products Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chongqing Zhifei Biological Products Co., Ltd. entered the biological products industry in 2002 and was listed on the Shenzhen Stock Exchange in September 2010 (stock code: 300122), becoming the first private vaccine enterprise to be listed on the ChiNext. It has five wholly-owned subsidiaries and two participating companies, Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. (referred to as "Zhifei Green Bamboo") and Anhui Zhifei Long Kema Biopharmaceutical Co., Ltd. (referred to as "Zhifei Long Kema") are high-tech enterprises. Zhifei Biotechnology is an international, full industry chain high-tech biopharmaceutical enterprise that integrates research and development, production, sales, distribution, and import and export of vaccines and biological products. Its main business is the seven strategic emerging industries in China, with broad development prospects. Current products include recombinant novel coronavirus protein vaccine (CHO cell) (Zhikeweide), recombinant tuberculosis fusion protein (EC, Yika), ACYW135 meningococcal polysaccharide vaccine (Mengweike), group A and group C meningococcal polysaccharide conjugate vaccine (Mengnakang), haemophilus influenzae type b conjugate vaccine (Hifebe) All imported vaccines, including independent products such as Mycobacterium bovis for injection (Microcard), and uniformly sold four valent human papillomavirus vaccine (Saccharomyces cerevisiae), nine valent human papillomavirus vaccine (Saccharomyces cerevisiae), oral five valent reconstituted live attenuated rotavirus vaccine (Vero cells), 23 valent pneumococcal polysaccharide vaccine, and inactivated hepatitis A vaccine (human diploid cells) from MSD. Through the dual wheel drive model of "technology+market", the company has formed a good circulation mechanism of market and research and development promoting and transforming each other, accelerating the process of vaccine products from research and development to market value conversion, and gradually forming a unique and leading core competitiveness in the market. The company has established a high-quality expert research and development team, focusing on the introduction and development of research and development technology. It has participated in more than 20 major projects, including the "Modern Medical Technology" project of the 863 Plan of the Ministry of Science and Technology, the major new drug development project of the Ministry of Science and Technology, and the national major special project for new drug development. The company has 29 independent research projects, including those that are applying for document number, obtaining clinical approval documents and pre clinical projects. The products mainly involve vaccine projects for prevention of tuberculosis, COVID-19, epidemic cerebrospinal meningitis, pneumonia, influenza, rabies, norovirus infection, etc. The research and development products have clear echelon structure and rich levels. At the same time, the company plans to expand into the field of large organisms and enter the therapeutic biological products industry according to its strategic development needs. In addition, the company has built a comprehensive and in-depth terminal service network, providing continuous, fast, and comprehensive high-quality services to more than 30000 grassroots health service points (township vaccination points, community clinics) in 31 provinces, autonomous regions, and municipalities across the country. Since its establishment, the company has always adhered to the corporate philosophy of "social benefits first, corporate benefits second" and the core values of "six first, six second". With the responsibility of improving national awareness of health prevention, it has successively introduced more than ten vaccine products for preventing multiple diseases into the market, playing a certain role in promoting the development of social public health and creating good social benefits. As of the first half of 2021, the company has accumulated over 6.8 billion yuan in taxes. In addition, the company regards social welfare undertakings as an important channel for giving back to society and assuming social responsibility, with a cumulative donation of nearly 400 million yuan in recent years. After more than ten years of hard development, the company has been recognized by all walks of life, and has won honorary titles such as exemplary individual of private economy in the national fight against the COVID-19, the top 100 party organizations in the national non-public enterprises, the national "contract abiding and trustworthy" enterprise, the national commercial integrity pilot enterprise, the top 100 enterprises in the pharmaceutical industry, China AAA credit enterprise, the national integrity management demonstration unit, etc. |
| Headquarter | Chongqing |
| Establish Date | 7/20/1995 |
| Listed Code | 300122.SZ |
| Listed Date | 9/28/2010 |
| Chairman | Jiang Rensheng. |
| CEO | Jiang Rensheng. |
| Website | www.zhifeishengwu.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
